Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 12, 2012 - Issue 12
Submit an article Journal homepage
137
Views
5
CrossRef citations to date
0
Altmetric
Review

Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the ‘common arm’ approach

Philip C Mack Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA 95817, USA; Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA 95817, USA
,
David R Gandara Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA 95817, USA; Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA 95817, USA
&
Primo N Lara Jr Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA 95817, USA; Veterans Administration Northern California Health Care System, Mather, CA, USA. [email protected]; Veterans Administration Northern California Health Care System, Mather, CA, USA. [email protected]
Pages 1591-1596 | Published online: 10 Jan 2014

References

  • Malinowski HJ, Westelinck A, Sato J, Ong T. Same drug, different dosing: differences in dosing for drugs approved in the United States, Europe, and Japan. J. Clin. Pharmacol. 48(8), 900–908 (2008).
  • Arnold FL, Kusama M, Ono S. Exploring differences in drug doses between Japan and western countries. Clin. Pharmacol. Ther. 87(6), 714–720 (2010).
  • Thiers FA, Berndt AR. From the analyst’s couch: trends in the globalization of clinical trials. Nat. Rev. Drug Dis. 7, 13–14 (2008).
  • Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18(10), 2095–2103 (2000).
  • Hanna N, Shepherd FA, Fossella FV et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22(9), 1589–1597 (2004).
  • Maruyama R, Nishiwaki Y, Tamura T et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J. Clin. Oncol. 26(26), 4244–4252 (2008).
  • Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br. J. Cancer 91(Suppl. 2), S18–S23 (2004).
  • Camus P. Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management. Br. J. Cancer 91(Suppl. 2), S1–S2 (2004).
  • Sekine I, Yamamoto N, Nishio K, Saijo N. Emerging ethnic differences in lung cancer therapy. Br. J. Cancer 99(11), 1757–1762 (2008).
  • Gandara DR, Kawaguchi T, Crowley J et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J. Clin. Oncol. 27(21), 3540–3546 (2009).
  • Noda K, Nishiwaki Y, Kawahara M et al.; Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 346(2), 85–91 (2002).
  • Lara PN Jr, Gandara DR, Natale RB. Randomized Phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer. Clin. Lung Cancer 7(5), 353–356 (2006).
  • Lara PN Jr, Chansky K, Shibata T et al. Common arm comparative outcomes analysis of Phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small-cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124. Cancer 116(24), 5710–5715 (2010).
  • Sekine I, Nokihara H, Yamamoto N et al. Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small-cell lung cancer. Lung Cancer 53(2), 157–164 (2006).
  • Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial – INTACT 2. J. Clin. Oncol. 22(5), 785–794 (2004).
  • Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial–INTACT 1. J. Clin. Oncol. 22(5), 777–784 (2004).
  • Georgoulias V, Ardavanis A, Tsiafaki X et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a Phase III randomized trial. J. Clin. Oncol. 23(13), 2937–2945 (2005).
  • Ohe Y, Ohashi Y, Kubota K et al. Randomized Phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann. Oncol. 18(2), 317–323 (2007).
  • Kawahara M. Phase III randomized study of vinorelbine, gemcitabine followed by docetaxel versus paclitaxel and carboplati in patients with advanced non-small-cell lung cancer: Japan Multinational Trial Organization LC00-03). J. Clin. Oncol. 24, Abstract 7013 (2006).
  • Williamson SK, Crowley JJ, Lara PN Jr et al.; Southwest Oncology Group Trial S0003. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J. Clin. Oncol. 23(36), 9097–9104 (2005).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.